. 2016 Aug 17;2(4):222–232. doi: 10.1016/j.trci.2016.07.001

Table 3.

Agents currently in phase I of development and their mechanism of action (as of 1/4/2016)

Agent	Agent mechanism class	Mechanism of action	Clinicaltrials.gov ID	Sponsor	Start date	Estimated end date
AADvac1	Anti-tau	Monoclonal antibody directed at Tau epitope	NCT02031198	Axon Neuroscience	Jan 14	Sep 17
ABT-957	Neuroprotective	Calpain inhibitor	NCT02220738	AbbVie	Sep 14	Jun 16
ABT-957	Neuroprotective	Calpain inhibitor	NCT02573740	AbbVie	Nov 15	Nov 16
Aducanumab	Anti-amyloid	Monoclonal antibody	NCT01677572	Biogen	Oct 12	Oct 19
Aducanumab	Anti-amyloid	Monoclonal antibody	NCT02434718	Biogen	May 15	Jul 17
Allopregnanolone injection	Neuroprotective	GABA receptor modulator	NCT02221622	University of Southern California	Aug 14	Mar 17
BI 409306	Neurotransmitter based	PDE 9A inhibitor	NCT02392468	Boehringer Ingelheim	Apr 15	Oct 16
Bisnorcymserine (BNC)	Neurotransmitter based	Butyrylcholinesterase inhibitor	NCT01747213	National Institute on Aging (NIA)	Nov 12	Jul 17
Crenezumab	Anti-amyloid	Monoclonal antibody	NCT02353598	Genentech	Feb 15	Sep 17
CT1812	Anti-amyloid	Sigma-2 receptor modulator; reduces amyloid toxicity	NCT02570997	Cognition Therapeutics	Sep 15	Jun 16
GC021109	Anti-inflammatory, neuroprotective	Anti-inflammatory	NCT02386306	GliaCure	Feb 15	Oct 15
Insulin Aspart Intranasal	Metabolic	Insulin	NCT02462161	Wake Forest School of Medicine	May 15	Dec 16
JNJ-54861911	Anti-amyloid	BACE inhibitor	NCT02360657	Janssen	Feb 15	Sep 15
KHK6640	Anti-amyloid	Amyloid aggregation inhibitor	NCT02127476	Kyowa Hakko Kirin Pharma	Jul 14	Feb 17
KHK6640	Anti-amyloid	Amyloid aggregation inhibitor	NCT02377713	Kyowa Hakko Kirin Pharma	Mar 15	Dec 16
Lorazepam	Neurotransmitter based	Benzodiazepam	NCT01780519	Mayo Clinic	Jan 13	Sep 16
Lu AF20513	Anti-amyloid	Monoclonal antibody	NCT02388152	H. Lundbeck A/S	Mar 15	Dec 16
LY2599666 + Solanezumab	Anti-amyloid	Monoclonal antibody combination	NCT02614131	Eli Lilly and Company	Dec 15	Jul 17
LY3002813	Anti-amyloid	Monoclonal antibody	NCT01837641	Eli Lilly and Company	May 13	Sep 16
LY3202626	Anti-amyloid	Undisclosed mechanism	NCT02323334	Eli Lilly and Company	Dec 14	Feb 16
MEDI1814	Anti-amyloid	Monoclonal antibody	NCT02036645	AstraZeneca	Feb 14	Oct 16
NGP 555	Anti-amyloid	Gamma-secretase modulator	NCT02534480	NeuroGenetic Pharmaceuticals	Mar 15	Nov 15
Oxaloacetate	Metabolic	Mitochondrial enhancer	NCT02593318	University of Kansas Medical Center	Oct 15	Oct 17
PF-06751979	Anti-amyloid	Undisclosed mechanism	NCT02509117	Pfizer	Jul 15	Jul 16
S-Equol	Neuroprotective	Estrogen receptor beta agonist	NCT02142777	University of Kansas Medical Center	Jul 14	Dec 16
Telmisartan	Neuroprotective	PPAR-gamma agonist	NCT02471833	Emory University	Apr 15	Mar 18
TPI-287	Anti-tau	Microtubule protein modulator	NCT01953705	University of California, San Francisco	May 14	Mar 19

Abbreviations: BACE = beta-site amyloid precursor protein cleaving enzyme; GABA = gamma-aminobutyric acid; PDE = phosphodiesterase; PPAR = peroxisome proliferator-activated receptor.

NOTE. Twenty-four agents in 27 phase I clinical trials currently ongoing (active, not recruiting, and active, recruiting) as of January 4, 2016, according to clinicaltrials.gov.